# WIA-BIO-020 — Phase 1: Data Format > Regenerative-medicine canonical Phase 1: stem-cell + growth-factor + scaffold + clinical-application + QC envelopes. # WIA-BIO-020: Regenerative Medicine Specification v1.0 > **Standard ID:** WIA-BIO-020 > **Version:** 1.0.0 > **Published:** 2025-12-26 > **Status:** Active > **Authors:** WIA Regenerative Medicine Research Group --- ## Table of Contents 1. [Introduction](#1-introduction) 2. [Stem Cell Types and Classification](#2-stem-cell-types-and-classification) 3. [Regeneration Mechanisms](#3-regeneration-mechanisms) 4. [Tissue Engineering and Scaffolds](#4-tissue-engineering-and-scaffolds) 5. [Growth Factor Delivery Systems](#5-growth-factor-delivery-systems) 6. [Clinical Applications](#6-clinical-applications) 7. [Regulatory Requirements](#7-regulatory-requirements) 8. [Implementation Guidelines](#8-implementation-guidelines) 9. [Safety Protocols](#9-safety-protocols) 10. [References](#10-references) --- ## 2. Stem Cell Types and Classification ### 2.1 Embryonic Stem Cells (ESCs) **Source**: Inner cell mass of blastocyst (day 5-6 embryo) **Characteristics**: - Pluripotent: Can differentiate into all cell types - High proliferation rate - Express OCT4, SOX2, NANOG markers - Telomerase positive (unlimited division) **Applications**: - Disease modeling - Drug screening - Cellular therapy (pending ethical approval) **Culture Conditions**: ``` Medium: mTeSR1 or E8 Substrate: Matrigel or vitronectin Temperature: 37°C, 5% CO₂ Passage: Every 3-5 days (70-80% confluence) Pluripotency markers: OCT4⁺, NANOG⁺, SSEA-4⁺ ``` ### 2.2 Induced Pluripotent Stem Cells (iPSCs) **Source**: Reprogrammed somatic cells (fibroblasts, blood cells) **Reprogramming Factors** (Yamanaka Factors): - OCT4 (Octamer-binding transcription factor 4) - SOX2 (Sex determining region Y-box 2) - KLF4 (Kruppel-like factor 4) - c-MYC (Cellular myelocytomatosis oncogene) **Reprogramming Efficiency**: ``` η = (N_iPSC / N_initial) × 100% ``` Typical efficiency: 0.01% - 3% depending on method **Advantages**: - Patient-specific (autologous) - No ethical concerns - Unlimited cell source - Disease modeling in patient cells **Quality Control**: - Karyotype analysis (normal 46 chromosomes) - Pluripotency marker expression (>90%) - Teratoma formation assay - Differentiation potential to 3 germ layers - Epigenetic reprogramming verification ### 2.3 Mesenchymal Stem Cells (MSCs) **Sources**: - Bone marrow (BM-MSCs) - Adipose tissue (AD-MSCs) - Umbilical cord (UC-MSCs) - Dental pulp (DP-MSCs) **Defining Criteria** (ISCT 2006): 1. Plastic adherence 2. Positive markers: CD73⁺, CD90⁺, CD105⁺ (>95%) 3. Negative markers: CD45⁻, CD34⁻, CD14⁻, CD19⁻, HLA-DR⁻ (<2%) 4. Tri-lineage differentiation: osteogenic, adipogenic, chondrogenic **Differentiation Potential**: ``` Osteogenic: Bone (osteoblasts, osteocytes) Adipogenic: Fat (adipocytes) Chondrogenic: Cartilage (chondrocytes) Myogenic: Muscle (myocytes) Neurogenic: Neural cells (limited) ``` **Immunomodulatory Properties**: - Secrete IL-10, TGF-β, PGE2 - Suppress T-cell proliferation - Modulate macrophage polarization (M1→M2) - Low immunogenicity (low HLA class I, no HLA class II) ### 2.4 Hematopoietic Stem Cells (HSCs) **Source**: Bone marrow, peripheral blood, umbilical cord blood **Markers**: - Positive: CD34⁺, CD133⁺, CD90⁺ - Negative: Lineage markers (Lin⁻) **Differentiation**: ``` HSCs → Myeloid lineage → RBCs, platelets, granulocytes, monocytes HSCs → Lymphoid lineage → T cells, B cells, NK cells ``` **Clinical Use**: - Bone marrow transplantation - Treatment of leukemia, lymphoma - Sickle cell disease, thalassemia - Immune deficiencies --- ## 5. Growth Factor Delivery Systems ### 5.1 Key Growth Factors | Growth Factor | Function | Target Cells | Optimal Dose | |--------------|----------|--------------|--------------| | VEGF | Angiogenesis | Endothelial cells | 10-50 ng/ml | | FGF-2 | Cell proliferation | Multiple | 5-20 ng/ml | | TGF-β | ECM production | Fibroblasts | 1-10 ng/ml | | BMP-2 | Bone formation | Osteoblasts | 50-200 ng/ml | | PDGF | Wound healing | Fibroblasts | 10-100 ng/ml | | IGF-1 | Cell growth | Multiple | 50-200 ng/ml | | EGF | Epithelial growth | Keratinocytes | 5-50 ng/ml | | BDNF | Neurogenesis | Neurons | 10-100 ng/ml | | NGF | Nerve growth | Neurons | 50-200 ng/ml | ### 5.2 Delivery Methods #### 5.2.1 Bolus Injection **Advantages**: Simple, immediate effect **Disadvantages**: Short half-life, burst release **Pharmacokinetics**: ``` C(t) = C₀ × e^(-kt) ``` Half-life: 2-24 hours for most growth factors #### 5.2.2 Scaffold-Based Delivery **Release Kinetics**: ``` M_released(t) = M_total × (1 - e^(-kt)) ``` **Release Patterns**: - Immediate release: 50-80% in 24h - Sustained release: 10-20% per week - Controlled release: Programmed pattern #### 5.2.3 Encapsulation (Microspheres) **Size Range**: 1-200 μm **Release Mechanisms**: 1. Diffusion through polymer matrix 2. Polymer degradation 3. Osmotic pressure **Encapsulation Efficiency**: ``` E_eff = (M_encapsulated / M_initial) × 100% ``` Target: >70% #### 5.2.4 Gene Delivery (Plasmid/Viral) **Viral Vectors**: - Adenovirus: High efficiency, transient - Lentivirus: Stable integration - AAV: Safe, long-term expression **Non-Viral**: - Plasmid DNA - mRNA - Lipid nanoparticles ### 5.3 Combination Therapy **Synergistic Effects**: ``` Effect_combined > Effect_A + Effect_B ``` **Examples**: - VEGF + FGF-2: Enhanced angiogenesis (2-3× increase) - BMP-2 + TGF-β3: Improved bone formation - NGF + BDNF: Superior neural regeneration --- --- ## A.1 Stem-cell-record envelope The Phase 1 envelope groups stem-cell records by source class (embryonic stem cell — ESC; mesenchymal stem cell — MSC from bone-marrow / adipose / umbilical-cord / dental pulp; hematopoietic stem cell — HSC; neural stem cell — NSC; induced pluripotent stem cell — iPSC reprogrammed from somatic donor cells) with the canonical fields: cell-record identifier (pseudonymous; consent-bound to the donor's WIA-A11Y attestation chain), donor metadata (ID, age, sex, ethnicity where consented, lot number), passage number, viability at thaw in %, sterility status (mycoplasma-free per USP <63>; endotoxin per USP <85> at less than 0.5 EU/mL), karyotype (for stem cells; G-band karyotyping is required for clinical-grade preparations), differentiation-marker panel (CD markers for MSC: CD73+ CD90+ CD105+ CD34- CD45- CD11b- CD19- CD79a- HLA-DR-), and the chain-of-custody hash that ties the cells to the contributing institution's signing key. ## A.2 Growth-factor descriptor Growth-factor descriptors carry: factor identifier (BMP-2 / BMP-7 / TGF-beta / VEGF / PDGF / FGF-2 / IGF-1 / NGF / GDNF / EGF / HGF / SDF-1), source (recombinant in E. coli / yeast / mammalian; native isolated from platelet-rich-plasma; cell-free conditioned medium), purity per HPLC, biological-activity per the standard activity-assay envelope, the formulation envelope (lyophilised, liquid carrier with the buffer composition, with-or-without carrier protein), and the storage envelope (typical -20 C to -80 C with the documented stability profile). Clinical-grade descriptors cross-reference the Phase 4 §A.3 regulatory envelope. ## A.3 Scaffold-and-delivery descriptor Scaffold-and-delivery descriptors carry the scaffold-of-record per the canonical material classification (cross-reference WIA-BIO-006 tissue-engineering Phase 1 §A.1 for the comprehensive material catalogue), the delivery-vehicle envelope (injectable hydrogel; in-situ-forming gel; pre-formed scaffold; microsphere-encapsulated; cell-laden bioink), the cell-density envelope (1e6-1e8 cells/mL typical for therapeutic injection; tissue-specific densities per Phase 1 §A.4), and the release-profile envelope (sustained-release of growth factors per the operator's pharmacokinetic study). The descriptor cross-references the IPSC reprogramming-vector envelope where iPSCs are derived in-house. ## A.4 Clinical-application descriptor Clinical-application descriptors carry: indication identifier per WHO ICD-11 + SNOMED-CT, target tissue, intended-clinical-effect envelope (replace lost tissue / promote endogenous regeneration / immunomodulate), trial-stage envelope (preclinical / phase 1 safety / phase 2 dose-finding-and-efficacy / phase 3 confirmatory / post-market surveillance), comparator-arm envelope (placebo / standard-of-care / no-intervention with the matching ethics-board approval), per-trial endpoint envelope (primary safety, primary efficacy, secondary endpoints, exploratory biomarkers), and the registration envelope (ClinicalTrials.gov / EU CTIS / KR CRIS / WHO ICTRP identifiers). ## A.5 Quality-test envelope Quality-test envelopes for cell-therapy products follow the cross-walk in Phase 4 §A.1 plus the cell-therapy-specific tests: identity (STR profiling for human cells; immunophenotyping per the marker-panel envelope), purity (residual-host-protein / DNA / serum / antibiotics), potency (per indication-specific functional assay — bone-formation per ALP+OCN secretion; cartilage per GAG production; cardiac per beating-rate-and-electrophysiology; neurological per dopaminergic-marker expression for Parkinson's-disease iPSC-derived neurons), tumourigenicity (soft-agar growth + immunodeficient-mouse xenograft), genetic stability (whole-genome-sequencing or array-CGH per the operator's release-test cadence), and microbiological safety (sterility per USP <71>; mycoplasma per USP <63>; endotoxin per USP <85>). --- ## Z.1 Glossary, conformance, governance A companion glossary at `https://wiastandards.com/regenerative-medicine/glossary/` expands every term used throughout this Phase. The conformance test suite at `https://github.com/WIA-Official/wia-regenerative-medicine-conformance` walks every endpoint and protocol exchange. The reference container at `wia/regenerative-medicine-host:1.0.0` ships every regenerative-medicine envelope and endpoint with mock data so integrators can exercise the contract before wiring real backends. The companion CLI at `cli/regenerative-medicine.sh` ships sample envelope generators with no dependencies beyond `jq` and POSIX shell. ## Z.2 Cross-standard composition (recap) This Phase composes with WIA-OMNI-API for credential storage, WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for federation handshake, WIA-INTENT for workload intent declaration, and (where personal data is processed) WIA Secure Enclave for sealed-data envelopes. The composition lets one host running multiple WIA family standards reuse one identity, one signing key chain, and one audit transport rather than maintaining N parallel implementations. ## Z.3 Implementation runbook A first implementation typically follows: stand up the reference container; run the conformance suite against it end-to-end; replace the mock backend with a real backend one endpoint at a time; wire audit-log replication out to the operations sink; onboard a single trusted peer for federation; expand to multiple peers; promote to production with the warning-envelope subscription enabled and the runbook in §Z.5 followed. ## Z.4 Backwards-compatibility promise Within the 1.x line, every Phase 1 envelope shape, every Phase 2 endpoint, and every Phase 3 protocol exchange MUST remain reachable and MUST continue to honour the documented status codes and content shapes. Hosts MAY add optional fields and new envelopes; hosts MUST NOT remove existing ones. Breaking changes ride a major version bump with a 12-month deprecation window per IETF RFC 8594 and 9745 and require a two-thirds Committee vote. ## Z.5 Closing implementer note This Phase fits inside the WIA Standards four-Phase architecture: Phase 1 envelopes are the wire-format contract; Phase 2 surfaces them through HTTPS; Phase 3 wraps them in protocol exchanges that cross trust boundaries; Phase 4 integrates with the broader ecosystem. Regenerative-medicine deployments that follow this layering inherit the per-Phase conformance gates and the cross-standard composition behaviour described in Z.2. 弘益人間 — Benefit All Humanity.